Role
Freelance UI/UX Designer
Challenge
Balancing strict FDA regulatory compliance with effective user experience
Deliverables
High-Fidelity mockups, UX/UI Components
Team setup
IMRE agency
Freelance designers
imre agency
I partnered with imre as a freelance UX/UI designer to assist in updating various Bavencio websites designs. The goal was to create a responsive, accessible experience that served healthcare professionals, patients, and caregivers with clear pathways and updated treatment resources. The final design improved navigation, mobile usability, and overall clarity while aligning with strict healthcare compliance standards.

Live Website: https://www.bavencio.com
Research
The problem
The Bavencio website was not meeting the needs of its core audiences: healthcare professionals, patients, and caregivers. The client asked for a redesign that would improve accessibility, responsiveness, and clarity while staying compliant with healthcare communication standards.
Discover and define
Business Challenges
My role was to translate client and stakeholder feedback into a user-focused digital experience. I delivered designs iteratively, using client feedback cycles to refine navigation, layout, and content presentation. I worked closely with the imre team to:

Navigation Issues

‍Navigation was difficult, making it hard to find treatment resources.

Poor Optimization

‍‍The site design was not fully optimized for mobile or tablet users.

Content Update

‍‍Content updates from the client had not been consistently applied, leading to gaps and outdated information.
The Approach
Reduce Friction Through Iteration
My role was to translate client and stakeholder feedback into a user-focused digital experience. I delivered designs iteratively, using client feedback cycles to refine navigation, layout, and content presentation. I worked closely with the imre team to:

Audit

‍Audit existing site flows and identify friction points.

Update

‍‍‍Update content structures so users could quickly determine if Bavencio was a treatment option worth discussing with their healthcare provider.

Create

‍‍‍Create responsive wireframes and high-fidelity mockups in line with brand guidelines.
Ideate
Jumping Into an Ongoing Project
In an agency, evolution and change happens quick. So upon joining this project I immediately needed to get to work on revising existing mockups from Adobe XD into figma as well as addressing our client feedback provided iterative updates that get pushed to a routing system.
Zoomed-out view of multiple Adobe XD design layout screens for desktop and mobile, showing detailed UI elements and text content.
Improvements
File Quality
My role was to translate client and stakeholder feedback into a user-focused digital experience. I delivered designs iteratively, using client feedback cycles to refine navigation, layout, and content presentation. I worked closely with the imre team to:

Teamwork Improved

‍Drastically improved speed of revisions as repeat work was reduced for components and standardization across all supported efforts.

Increased Accuracy

‍Future improvements and iterations were made faster and more accurately.

Improve Brand Trust

‍Bavencio website was more consistent across mobile through web user experience.
Mobile Components
Mobile Components layout showing various UI elements including safety information, NCCN category label, expandable menus with patient information, treatment approach cards, alert and callout boxes, accordion usage, anchor link lists, and bullet text blocks.
Desktop Components
Dashboard showing multiple desktop components including navigation menu, NCCN category listings, a detailed accordion with medical treatment data, banner with personalized treatment goals, and a long text ISI section.
Final Mockups for Developer Handoff
Below are the finalized mockups provided to the team at the end of my tenure with the IMRE team. Please note that these final products may have been subject to change on the live site at any time.
Desktop Workflow
Home page
Bavencio homepage showing a banner with three older men playing chess outside, promoting personalized treatment goals with Bavencio 1L maintenance, highlighting broad patient experience, established safety profile, and long-term overall survival data, plus NCCN Category 1 recommendation.
Identifying Patient Needs
Bavencio clinical considerations page titled 'Identifying Personalized Treatment Goals' featuring deeper discussions to strategize patient needs with PCC for 1L, la/mUC treatment, highlighting patient preference for better treatment experience over overall survival (OS) benefit and oncologist preference to improve OS. Video placeholder about Dr. Smith's individualized treatment approach to UC. Data notes ~80% of patients eligible for 1L platinum-containing chemotherapy, with about 8 in 10 patients achieving disease control in randomized trials. Emphasizes potential survival benefit of subsequent 1L maintenance treatment. Navigation menu at top and logo with related clinical data links at bottom.
Study Design
Study Design page
Efficacy - Tab 1
Bavencio efficacy page showing overall survival data graph comparing Bavencio plus BSC versus BSC alone in advanced urothelial carcinoma, with detailed safety and patient information.
Efficacy - Tab 2
BAVENCIO clinical efficacy webpage showing additional data from the JAVELIN Bladder 100 trial with graphs and statistics on median overall survival (mOS) comparing BAVENCIO + BSC versus BSC alone in platinum-containing chemotherapy patients; includes mOS of 29.7 months versus 20.5 months respectively, treatment durations, percentage of patients on therapy at 12 and 24 months, and safety information highlighting risks of severe/fatal immune-related adverse reactions. The page also features NCCN Category 1 recommendation for BAVENCIO in urothelial carcinoma, patient profiles, and links to real-world evidence and instructional videos.
Efficacy - Tab 3
Bavencio efficacy webpage section showing patient-reported outcomes from JB100 study, including a graph of FBISI-18 scores over 24 treatment cycles indicating little change between Bavencio plus BSC and BSC alone in overall population. Four symptom subscales listed: Physical (pain, weight loss, urination issues, fatigue), Emotional (worry, sadness), Treatment Side Effects (nausea, lack of energy, bowel control), and Functional Well-Being (ability to enjoy life). Limitations of the study mentioned, with reference notes and a call to action to review patient profiles for 1L maintenance treatment appropriateness. National Comprehensive Cancer Network recommendation highlights Bavencio as NCCN Category 1 immunotherapy for urothelial carcinoma. Navigation options and safety/patient profiles/real-world evidence links appear at the bottom.
Hidden Efficacy
Webpage about BAVENCIO® (avelumab) showing real-world evidence across heterogeneous patient populations. It includes a section on limitations of real-world data listing factors like lack of randomization, small sample size, and recall bias. A bar chart compares median overall survival from start of BAVENCIO maintenance therapy in three studies: JB100 (23.8 months), READY CUP (26.2 months), and PATRIOT II (24.4 months). Study design details for READY CUP (Italian compassionate use study) and PATRIOT II (US multicenter retrospective review) are summarized. A safety summary table for PATRIOT II with 160 patients lists adverse reactions, therapy modifications, and outcomes. A highlight notes real-world safety measures are consistent with JB100 trial. Navigation links for efficacy, safety, and patient profiles appear at the bottom.
Safety
Bavencio safety profile summary showing adverse reactions table comparing European Union and US FDA data, primary and long-term analysis statistics on Grade 3 or higher TRAEs, laboratory abnormalities table, and notes on no new safety signals in long-term follow-up; includes sections on patient profiles, dosing, and detailed safety information with disclaimers and references.
Patient Profile
Webpage from Bavencio presenting patient profiles and treatment information, featuring a case study of Vick, a 91-year-old male patient with recently diagnosed metastatic urothelial carcinoma (UC). The page includes treatment goals, patient details, medical history, and UC history sections. A video placeholder highlights how Bavencio 1L maintenance may benefit patients like Vick. The site also shows dosing and mechanism of action navigation and detailed important safety information and indications about Bavencio treatment, including warnings, precautions, and adverse reactions. The Bavencio logo appears at the top with navigation links and a call to action button.
Dosing
Screenshot of a regulatory agency webpage detailing COVID-19 vaccine dosing information, including dosage schedules, storage guidelines, and safety data.
Mechanism of Action
Diagram illustrating the mechanism of action of Bavencio, a PD-L1 inhibitor that activates dual immune function by restoring adaptive immunity and engaging innate immunity. It shows a T cell with a PD-1 receptor interacting with a tumor cell expressing PD-L1, with Bavencio blocking PD-L1 to restore T cell-mediated immune response. On the other side, an NK cell with Fcγ receptor interacts with the tumor cell, where Bavencio also acts to enable NK cell-mediated tumor cell lysis via ADCC. Text notes preclinical and in vitro data may not correlate with clinical outcomes.
Access and Resources
Bavencio website page titled Access and Resources for Your Patients and Practice, featuring sections with downloadable resources for healthcare professionals, nurse resources, EHR resources, patient resources, and CoverOne patient support with contact information and a video library on urothelial carcinoma treatment, followed by detailed safety information and indications for Bavencio medication.
Mobile Workflow
Home
Infographic titled 'Strategies for Freshman RA Recruitment 2022' with steps for recruitment, testimonials, NCCN Category 1 accreditation details, and information on recruitment strategies, marketing, tools, and medications.
Patient Needs
Informational graphic for Bavencio (avelumab) targeting patients with locally advanced or metastatic urothelial carcinoma (UC). The header states Clinical Considerations for Identifying Personalized Treatment Goals. Key message: deeper discussions help strategize patient care using preferred regimens that improve treatment experience and overall survival (OS). Oncologists strongly prefer treatments that improve OS. About 80% of patients are eligible for first-line platinum-containing chemotherapy, but many are not treated with it. Approximately 8 in 10 patients achieved disease control in randomized trials of Bavencio maintenance after platinum chemotherapy. Bavencio maintenance is recommended as NCCN Category 1 immunotherapy for certain UC patients not progressed on first-line treatment. The bottom lists references and clarifies Bavencio use as a maintenance option based on high-evidence guidelines.
Study Design
Infographic for the JAVELIN BLADDER 100 Trial study design on locally advanced or metastatic urothelial carcinoma (UC). It describes a phase 3, multicenter, randomized, open-label study with 700 patients who had advanced or metastatic UC not progressing after first-line platinum-containing chemotherapy. Includes diagrams of study phases, eligibility and exclusion criteria listing requirements such as measurable lesion, prior chemotherapy cycles, and no autoimmune diseases needing immunosuppression. Additional details on study administration, tumor assessment, and baseline patient characteristics with charts covering age, sex, race, ECOG PS, PD-L1 tumor status, metastasis sites, and chemotherapy response. A pie chart shows first-line chemotherapy regimens used. The image promotes learning more about patient profiles for treatment with BAVENCIO.
Efficacy - Tab 1
Infographic detailing BAVENCIO efficacy for primary, long-term, and exploratory safety outcomes in urothelial carcinoma. Key sections include the STRATEGIC trial demonstrating extended overall survival with BAVENCIO 1L maintenance compared to best supportive care, showing survival curves and statistical data. Long-term analysis shows consistent overall response in patients over 3 years. Safety information states BAVENCIO's consistent safety profile for advanced/metastatic urothelial carcinoma. Additional sections display duration of treatment, percentage of patients on BAVENCIO with specific treatment intervals, patient-reported outcomes, and comparison of BAVENCIO in clinical trial populations. The infographic ends with the NCCN Category 1 logo for BAVENCIO.
Efficacy - Tab 2
BAVENCIO Efficacy data summary showing primary, long-term, and exploratory analyses from the JAVELIN Bladder 100 trial of avelumab plus best supportive care versus best supportive care alone in advanced bladder cancer patients. Includes long-term exploratory analyses with survival curves for overall survival (mOS) from start of 1L platinum-containing chemotherapy and 1L chemotherapy only, with hazard ratios and median survival times. Selected safety information highlights immune-mediated adverse reactions. Patient-reported outcomes mention open-label design and limited patient numbers. FBSI-18 analysis assessed impact on fatigue, with a graph comparing avelumab plus BSC and BSC alone. The image also features NCCN Category 1 recommendation for avelumab maintenance therapy in metastatic urothelial carcinoma and a banner to watch a video about BAVENCIO treatment efficacy.
Efficacy - Tab 3
Bavencio efficacy webpage shows patient-reported outcomes, FBISI-18 bladder cancer symptom analysis graphs, limitations, and NCCN Category 1 recommendation for Avelumab maintenance in advanced or metastatic urothelial carcinoma, with a section to watch an expert video and links to patient profiles and real-world data.
Hidden Efficacy
Infographic titled 'Real-World Evidence Across Heterogenous Patient Populations Taking BAVENCIO' featuring a photo of diverse healthcare professionals. Key points highlight limitations of real-world data such as varied data sources, incomplete data, biases, and patient reporting errors. Study designs section describes the prospective, noninterventional Ready Cup study and the retrospective PATRIOT II study on aBMs with BAVENCIO. Summary of safety in PATRIOT II (N=160) includes tables with percentages of adverse events like AnyTRAR, immune-related TRARs, therapy stoppage or delay, steroid use, outcomes, durations, and hospitalizations due to TRARs. Text emphasizes consistent safety outcomes with prior studies and invites viewers to learn more by viewing efficacy, safety, and patient profiles. Navigation icons for efficacy, safety, and patient profiles are at the bottom.
Safety
Bavencio safety summary showing adverse reactions and long-term analysis data in patients receiving Bavencio with BSC. Primary analysis lists adverse reactions including fatal events, serious adverse reactions in ≥1%, and immune-mediated reactions with corticosteroid treatment. Tables detail adverse reactions and laboratory abnormalities worsening from baseline. Primary and long-term analyses display percentages of patients with Grade ≥3 treatment-related adverse reactions (TRARs) and immune-related adverse reactions (irARs), plus treatment discontinuation due to ARs and TRARs. No new safety signals observed in median follow-up ≥38 months. Nearly 20% of patients continued treatment after 2 years. Data noted as exploratory.
Patient Profile
Infographic titled 'Strategize for Bavencio IL Maintenance by Identifying Appropriate Patients' for advanced or metastatic urothelial carcinoma (UC). It explains that patient profiles are hypothetical for discussion. Data shows Bavencio plus BSC superior to BSC alone in median overall survival (19.6 vs 10.0 months) and progression-free survival. Patient profile highlights Vick, an 81-year-old cisplatin-ineligible UC patient with comorbidities, outlining treatment goals, clinical characteristics, medical history, and exclusion from cisplatin eligibility. Subgroup analysis for patients aged ≥80 shows median overall survival of 24.9 months with Bavencio plus BSC vs 10.0 months with BSC alone. Exploratory study limitations and full efficacy data links are included.
Dosing
Screenshot of a detailed webpage displaying cryptocurrency wallet information, including account balances, transaction details, and various controls for managing crypto assets.
Mechanism of Action
Infographic titled 'Mechanism of Action' for Bavencio (avelumab) showing its dual immune function as a PD-L1 inhibitor. It explains Bavencio activates adaptive immunity by blocking PD-L1 interaction with PD-1 receptors on T cells to restore T cell-mediated immune response, and innate immunity by inducing NK cell-mediated tumor cell lysis via ADCC. Sections include 'ADAPTIVE IMMUNE RESPONSE' describing release of T cell suppression, and 'INNATE IMMUNE RESPONSE' describing NK cell-mediated cytotoxicity in vitro. Includes reference to Bavencio prescribing information.
Access and Resources
Webpage titled 'Access and Resources for Your Patients and Practice' by Bavencio with sections for healthcare professionals including product information sheet, dosing and treatment guide, nurse resources like adverse reaction checklist and nurse handbook, EHR resources, and patient resources such as brochures and wallet cards. It also features CoverOne payment support with contact info and a video library of expert talks on urothelial carcinoma treatment.
Previous ProjectNext Project
arrow_upward
© Chris Wenzel 2026